Search Database

Name

Binimetinib

Alternate Names

MEKTOVI
MEK162

Abbreviations

None

Category

Chemotherapy

Subcategory

MEK 1/2 Inhibitor

NSC Number

None

Primary Site

None

Histology

Melanoma

Remarks

June 27, 2018: FDA approved encorafenib and binimetinib (BRAFTOVI and MEKTOVI) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Coding

This drug should be coded
Glossary